Biodesix, Inc. (BDSX) has a negative trailing P/E of -3.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -31.09%.
Criteria proven by this page:
Overall SharesGrow Score: 47/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | -13.0 | 0.00 | -1.72 | 16.64 | - |
| 2019 | -381.2 | 3.95 | -51.24 | 477.00 | - |
| 2020 | -62.2 | -0.07 | 47.39 | 42.82 | - |
| 2021 | -3.4 | -0.01 | 7.34 | 2.66 | - |
| 2022 | -1.5 | 0.78 | 4.70 | 2.53 | - |
| 2023 | -2.9 | 0.05 | 32.99 | 3.08 | - |
| 2024 | -4.6 | 0.10 | 9.50 | 2.78 | - |
| 2025 | -1.5 | 0.05 | -20.83 | 0.58 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-0.99 | $20.43M | $-26.17M | -128.1% |
| 2019 | $-1.23 | $24.55M | $-31.36M | -127.7% |
| 2020 | $-1.37 | $45.56M | $-36.47M | -80.1% |
| 2021 | $-1.63 | $54.51M | $-44.48M | -81.6% |
| 2022 | $-1.91 | $38.21M | $-80.39M | -210.4% |
| 2023 | $-0.64 | $49.09M | $-52.15M | -106.2% |
| 2024 | $-0.33 | $71.32M | $-42.93M | -60.2% |
| 2025 | $-4.67 | $88.5M | $-35.27M | -39.8% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-3.07 | $-3.10 – $-3.04 | $108.69M | $107.82M – $109.39M | 3 |
| 2027 | $-1.95 | $-1.96 – $-1.93 | $129.4M | $127.97M – $130.82M | 3 |
| 2028 | $-1.33 | $-1.46 – $-1.20 | $152.1M | $150.89M – $153.08M | 2 |
| 2029 | $-0.68 | $-0.69 – $-0.67 | $171.5M | $170.13M – $172.61M | 1 |
| 2030 | $-0.24 | $-0.24 – $-0.24 | $193.6M | $192.06M – $194.85M | 1 |
